Brief: ProKidney confirms Phase 3 program for autologous kidney cell therapy REACT
12/04/2022 13:15
April 12 (Reuters) - Social Capital Suvretta Holdings Corp
III DNAC.O :
* PROKIDNEY CONFIRMS PHASE 3 PROGRAM FOR AUTOLOGOUS KIDNEY
CELL
THERAPY REACT®
Source text for Eikon: ID:nGNXl93Jv
Further company coverage: DNAC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Prokidney
See all newsProkidney Corp reports results for the quarter ended September 30 - Earnings Summary
ProKidney Q3 loss widens on higher R&D costs
Brief: ProKidney Q3 Operating Income USD -53.758 Million
Brief: Prokidney Corp Enters Open Market Sale Agreement With Jefferies
Cell therapy developer ProKidney's Q2 operating loss widens as trial costs rise